Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy
Oncoscience · 28.07.2026 · 132026 · 250
DOI: 10.18632/oncoscience.667 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncoscience, online erschienen am 28.07.2026. Verfasst von Ronald Jemmerson. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Minnesota, Minneapolis, MN 55455, USA. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Leucine-rich alpha-2-glycoprotein-1 (LRG1) has received much attention as a prognostic indicator in cancer therapy where high serum levels generally predict a poor outcome.Recently, it has been shown to play an active role in cancer progression and is being pursued as a novel target in cancer therapy.LRG1 acts in neovascularization of tumors resulting in weakened blood vessels and ineffective delivery of chemotherapeutic drugs.A monoclonal antibody (mAb) against LRG1 has shown efficacy in blocking this function of LRG1, normalizing the vasculature, and improving drug delivery in mice.Extracellular LRG1 is also anti-apoptotic and promotes cell proliferation and metastasis, all through epidermal growth factor receptor family signaling.In mice, anti-LRG1 antibody therapy has been shown to inhibit these effects of extracellular LRG1 and to enhance the anti-cancer effect of immune checkpoint blockade (ICB) therapy in mice.Pre-clinical testing of the humanized version of the LRG1 mAb is underway in the United Kingdom.Intracellular LRG1 has been reported to inhibit apoptosis by blocking the binding of Cyt c to apoptotic protease activating factor1 (Apaf-1) and to have other cytoplasmic functions.A nanoscale proteolysis targeting chimera (nano-PROTAC) with improved cytoplasmic delivery has been developed which enhanced apoptosis in tumors of mice.Targeting LRG1 in the aberrant angiogenesis of endothelial cells and the LRG1-Cyt c-Apaf-1 axis in cancer cells, along with other putative intracellular interactions of LRG1, show potential as supplementary, if not alternative, approaches to cancer therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Minnesota, Minneapolis, MN 55455, USA.
Zitieren
APA
Jemmerson, R. (2026). Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy. Oncoscience, 132026, 250. https://doi.org/10.18632/oncoscience.667
Vancouver
Jemmerson R. Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy. Oncoscience. 2026;132026:250. doi:10.18632/oncoscience.667
BibTeX
@article{Jemmerson2026,
author = {Jemmerson, Ronald},
title = {Targeting leucine-rich alpha-2-glycoprotein-1 (LRG1) and the LRG1-cytochrome c-Apaf-1 axis in cancer therapy},
journal = {Oncoscience},
year = {2026},
volume = {132026},
pages = {250},
doi = {10.18632/oncoscience.667}
}
EUVIMED